Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
Guertin, Amy D, Li, Jing, Liu, Yaping, Hurd, Melissa S, Schuller, Alwin G, Long, Brian, Hirsch, Heather A, Feldman, Igor, Benita, Yair, Toniatti, Carlo, Zawel, Leigh, Fawell, Stephen E, Gilliland, D Gary, Shumway, Stuart D
Published in Molecular cancer therapeutics (01.08.2013)
Published in Molecular cancer therapeutics (01.08.2013)
Get full text
Journal Article
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1
Aarts, Marieke, Sharpe, Rachel, Garcia-Murillas, Isaac, Gevensleben, Heidrun, Hurd, Melissa S, Shumway, Stuart D, Toniatti, Carlo, Ashworth, Alan, Turner, Nicholas C
Published in Cancer discovery (01.06.2012)
Published in Cancer discovery (01.06.2012)
Get full text
Journal Article
Abstract 2051: Inhibitors against CHK1 and WEE1, MK-8776 and MK-1775, strongly synergize in vitro and in vivo to inhibit tumor growth
Shumway, Stuart D., Guertin, Amy D., Martin, Melissa M., Roberts, Brian, Hurd, Melissa S., Qu, Xianlu, Miselis, Nathan R., Bloecher, Andrew, Toniatti, Carlo
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Get full text
Journal Article
Abstract 2969: A Wee1 kinase inhibitor, MK-1775, sensitizes cervical carcinoma cell lines to cisplatin and topotecan
Shumway, Stuart D., Kubica, Jamie L., Guertin, Amy D., Hurd, Melissa S., Wexler, Roseanne S., Demuth, Tim, Toniatti, Carlo
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Get full text
Journal Article